Everolimus

Title: Everolimus
CAS Registry Number: 159351-69-6
CAS Name: 42-O-(2-Hydroxyethyl)rapamycin
Additional Names: 40-O-(2-hydroxyethyl)rapamycin
Manufacturers' Codes: RAD-001; SDZ RAD
Trademarks: Certican (Novartis)
Molecular Formula: C53H83NO14
Molecular Weight: 958.22
Percent Composition: C 66.43%, H 8.73%, N 1.46%, O 23.38%
Literature References: Macrolide immunosuppressant; derivative of rapamycin, q.v. Inhibits cytokine-mediated lymphocyte proliferation. Prepn: S. Cottens, R. Sedrani, WO 9409010; eidem, US 5665772 (1994, 1997 both to Sandoz). Pharmacology: W. Schuler et al., Transplantation 64, 36 (1997). Whole blood determn by LC/MS: N. Brignol et al., Rapid Commun. Mass Spectrom. 15, 898 (2001); by HPLC: S. Baldelli et al., J. Chromatogr. B 816, 99 (2005). Clinical pharmacokinetics in combination with cyclosporine: J. M. Kovarik et al., Clin. Pharmacol. Ther. 69, 48 (2001). Clinical study in prevention of cardiac-allograft vasculopathy: H. J. Eisen et al., N. Engl. J. Med. 349, 847 (2003). Review: F. J. Dumont et al., Curr. Opin. Invest. Drugs 2, 1220-1234 (2001); B. Nashan, Ther. Drug Monit. 24, 53-58 (2002).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.
Evodiamine Exalamide Exaltolide? Exemestane Exendins

Everolimus
Everolimus.svg
Everolimus ball-and-stick.png
Systematic (IUPAC) name
dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Clinical data
Licence data US FDA:link
Pregnancy cat. D (US)
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Half-life ~30 hours[1]
Identifiers
CAS number 159351-69-6 YesY
ATC code L01XE10 L04AA18
PubChem CID 6442177
DrugBank DB01590
ChemSpider 21106307 YesY
UNII 9HW64Q8G6G YesY
KEGG D02714 YesY
ChEMBL CHEMBL1201755 N
Synonyms 42-O-(2-hydroxyethyl)rapamycin
Chemical data
Formula C53H83NO14 
Mol. mass 958.224 g/mol
 N (what is this?)  (verify)

Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).

It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors for use in a number of cancers.

It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology. Everolimus also available with Biocon with the brand name of Evertor.